Inactive Instrument

Amarin Corporation plc (ADR) Share Price Xetra

Equities

EH3A

US0231112063

Biotechnology & Medical Research

Real-time Estimate Tradegate 04:36:20 28/06/2024 pm IST
0.675 EUR 0.00% Intraday chart for Amarin Corporation plc (ADR)

Financials

Sales 2024 * 20Cr 19Cr 1.68TCr Sales 2025 * 21Cr 20Cr 1.79TCr Capitalization 29Cr 27Cr 2.4TCr
Net income 2024 * -7Cr -6.54Cr -583.48Cr Net income 2025 * -6.4Cr -5.98Cr -533.47Cr EV / Sales 2024 * 1.21 x
Net cash position 2024 * 4.39Cr 4.1Cr 366.07Cr Net cash position 2025 * 16Cr 15Cr 1.32TCr EV / Sales 2025 * 0.6 x
P/E ratio 2024 *
-3.98 x
P/E ratio 2025 *
-4.21 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.48%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Amarin Corporation plc (ADR)

Managers TitleAgeSince
Chief Executive Officer 61 01/12/01
Director of Finance/CFO 52 20/22/20
Compliance Officer 55 15/11
Members of the board TitleAgeSince
Director/Board Member 45 28/23/28
Chairman 49 28/23/28
Director/Board Member 66 28/23/28
More insiders
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
More about the company